SpringWorks Shares Surge on Reported Acquisition Talks with Merck KGaA

The German healthcare giant is reportedly in advanced discussions to acquire the U.S.-based cancer and rare disease treatment developer.

SpringWorks Therapeutics' stock rose by over 30%, reaching its highest closing price since April 2022, following reports of acquisition talks with Merck KGaA.
Merck KGaA, a German healthcare and technology company, is reportedly in advanced discussions to acquire SpringWorks for its cancer and rare disease treatment portfolio.
SpringWorks, valued at $3 billion, specializes in therapies for cancer and rare diseases, including an FDA-approved treatment for desmoid tumors.
The acquisition would bolster Merck KGaA's oncology pipeline, which has faced setbacks, including halted trials for xevinapant and the failure of evobrutinib.
Neither company has confirmed the deal, but sources suggest an agreement could be finalized in the coming weeks, reflecting renewed interest in healthcare mergers.